Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy

Rama Soundararajan, Jared J. Fradette, Jessica M. Konen, Stacy Moulder, Xiang Zhang, Don L. Gibbons, Navin Varadarajan, Ignacio I. Wistuba, Debasish Tripathy, Chantale Bernatchez, Lauren A. Byers, Jeffrey T. Chang, Alejandro Contreras, Bora Lim, Edwin Roger Parra, Emily B. Roarty, Jing Wang, Fei Yang, Michelle Barton, Jeffrey M. RosenSendurai A. Mani

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Unfortunately, a significant portion of cancers (including lung and breast cancers) do not respond to immunotherapy, and many of them develop resistance to chemotherapy. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is mostly latent in adults, can be activated under selective pressures, rendering these cancers resistant to chemo-and immunotherapies. EMT can also drive tumor metastases, which in turn also suppress the cancer-fighting activity of cytotoxic T cells that traffic into the tumor, causing immunotherapy to fail. In this review, we compare and contrast immunotherapy treatment options of non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). We discuss why, despite breakthrough progress in immunotherapy, attaining predictable outcomes in the clinic is mostly an unsolved problem for these tumors. Although these two cancer types appear different based upon their tissues of origin and molecular classification, gene expression indicate that they possess many similarities. Patient tumors exhibit activation of EMT, and resulting stem cell properties in both these cancer types associate with metastasis and resistance to existing cancer therapies. In addition, the EMT transition in both these cancers plays a crucial role in immunosuppression, which exacerbates treatment resistance. To improve cancer-related survival we need to understand and circumvent, the mechanisms through which these tumors become therapy resistant. In this review, we discuss new information and complementary perspectives to inform combination treatment strategies to expand and improve the anti-tumor responses of currently available clinical immune checkpoint inhibitors.

Original languageEnglish (US)
Article number714
JournalCancers
Volume11
Issue number5
DOIs
StatePublished - May 2019
Externally publishedYes

Keywords

  • CD8 T Cells
  • Immune blockade
  • NSCLC
  • Reversal of EMT
  • TNBC
  • Tumor microenvironment
  • Tumor plasticity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy'. Together they form a unique fingerprint.

Cite this